{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:15:41Z","timestamp":1787786141384,"version":"build-2784847793"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006364","name":"French National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.radonc.2026.111443","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T16:39:18Z","timestamp":1770914358000},"page":"111443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Radiotherapy with twice weekly Gemcitabine and Cisplatin compared to Cisplatin alone for organ preservation in muscle-invasive bladder cancer: results of the GETUG V04 randomized phase II trial"],"prefix":"10.1016","volume":"217","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6302-825X","authenticated-orcid":false,"given":"Morgan","family":"Michalet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Ronchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4376-0697","authenticated-orcid":false,"given":"Thomas","family":"Reynaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4730-1161","authenticated-orcid":false,"given":"Nicolas","family":"Demogeot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Gourgou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Th\u00e9zenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Hannoun-L\u00e9vi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naji","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Quivrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9737-5655","authenticated-orcid":false,"given":"Olivier","family":"Riou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Charissoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7773-5481","authenticated-orcid":false,"given":"Carmen","family":"Llacer-Moscardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Tosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Durdux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazim","family":"Khalladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Culine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Azria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2026.111443_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.radonc.2026.111443_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2023.03.029","article-title":"Epidemiology of bladder cancer in 2023: a systematic review of risk factors","author":"Jubber","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2026.111443_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up5","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2026.111443_b0020","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111443_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.110038","article-title":"Quality of life after definitive treatment for bladder cancer: a systematic review and meta-analysis","volume":"190","author":"Francolini","year":"2024","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.radonc.2026.111443_b0030","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.ijrobp.2020.07.2122","article-title":"Bladder preservation with twice-daily radiation plus 5-flourouracil\/cisplatin or daily radiation plus gemcitabine for MIBC \u2013 updated results of NRG\/RTOG 0712: a randomized phase 2 trial","volume":"108","author":"Coen","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111443_b0035","article-title":"Bladder preservation with twice-a-day radiation plus fluorouracil\/cisplatin or once daily radiation plus gemcitabine for muscle-invasive bladder cancer: NRG\/RTOG 0712\u2014a randomized phase II trial","volume":"37","author":"Coen","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111443_b0040","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.eururo.2022.04.017","article-title":"Chemoradiotherapy in muscle-invasive bladder cancer: 10-yr follow-up of the phase 3 randomised controlled BC2001 trial","volume":"82","author":"Hall","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2026.111443_b0045","article-title":"Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: a pooled individual data analysis of eight phase I\u2013II trials","volume":"6","author":"Caffo","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111443_b0050","article-title":"Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial","author":"Kent","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111443_b0055","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","author":"Anon","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111443_b0060","doi-asserted-by":"crossref","unstructured":"Azria D, Riou O, Rebillard X, et al. Combined chemoradiation therapy with twice-weekly gemcitabine and cisplatin for organ preservation in muscle-invasive bladder cancer: long-term results of a phase 1 trial. 2014;88:7.","DOI":"10.1016\/j.ijrobp.2013.11.016"},{"key":"10.1016\/j.radonc.2026.111443_b0065","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S0360-3016(03)00763-6","article-title":"Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer","volume":"57","author":"Caffo","year":"2003","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111443_b0070","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/cncr.25667","article-title":"Gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer","volume":"117","author":"Caffo","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2026.111443_b0075","article-title":"The efficacy of trimodal chemoradiotherapy with gemcitabine and cisplatin as a bladder-preserving strategy for the treatment of muscle-invasive bladder cancer: a single-arm phase II study","volume":"52","author":"Kobayashi","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111443_b0080","doi-asserted-by":"crossref","unstructured":"Lemi\u0144ski A, Michalski W, Masoj\u0107 B, et al. Combined modality bladder-sparing therapy for muscle-invasive bladder cancer: how (should) we do it? A narrative review. 2023.","DOI":"10.3390\/jcm12041560"},{"key":"10.1016\/j.radonc.2026.111443_b0085","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.ijrobp.2021.03.001","article-title":"Long-term outcomes of radical radiation therapy with hypoxia modification with biomarker discovery for stratification: 10-year update of the BCON (bladder carbogen nicotinamide) phase 3 randomized trial (ISRCTN45938399)","volume":"110","author":"Song","year":"2021","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111443_b0090","unstructured":"Witjes JA. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines."},{"key":"10.1016\/j.radonc.2026.111443_b0095","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2021.09.026","article-title":"The 2021 updated european association of urology guidelines on metastatic urothelial carcinoma","volume":"81","author":"Cathomas","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2026.111443_b0100","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/ijgc-00009577-200505001-00004","article-title":"Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma","volume":"15","author":"Rose","year":"2005","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"},{"key":"10.1016\/j.radonc.2026.111443_b0105","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","article-title":"Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan","volume":"103","author":"Okusaka","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2026.111443_b0110","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1470-2045(20)30607-0","article-title":"Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials","volume":"22","author":"Choudhury","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111443_b0115","article-title":"Benefit of whole-pelvis radiation for patients with muscle-invasive bladder cancer: an inverse probability treatment weighted analysis","author":"Marcq","year":"2024","journal-title":"Invasive Bladder Cancer"},{"key":"10.1016\/j.radonc.2026.111443_b0120","article-title":"Effect of complete transurethral resection on oncologic outcomes after radiation therapy for muscle-invasive bladder cancer: transurethral resection in radiation therapy","author":"Avolio","year":"2024","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111443_b0125","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s00345-020-03440-4","article-title":"Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response","volume":"39","author":"Daro-Faye","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.radonc.2026.111443_b0130","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.clon.2021.02.014","article-title":"Is there a benefit of combining immunotherapy and radiotherapy in bladder cancer?","volume":"33","author":"Wilkins","year":"2021","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111443_b0135","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.euf.2022.12.012","article-title":"Efficacy and safety of pembrolizumab (MK-3475) in combination with chemoradiotherapy versus chemoradiotherapy alone in muscle-invasive bladder cancer: the MK-3475-992\/KEYNOTE-992 trial","volume":"9","author":"Tissot","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.radonc.2026.111443_b0140","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1016\/j.clon.2021.02.012","article-title":"Advancing radiotherapy for bladder cancer: randomised phase II trial of adaptive image-guided standard or dose-escalated tumour boost radiotherapy (RAIDER)","volume":"33","author":"Hafeez","year":"2021","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111443_b0145","article-title":"Dose-escalated adaptive radiotherapy for bladder cancer: results of the phase 2 RAIDER randomised controlled trial","author":"Huddart","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2026.111443_b0150","doi-asserted-by":"crossref","unstructured":"Walker AK. MRE11 as a predictive biomarker of outcome after radiation therapy in bladder cancer. 2019;104.","DOI":"10.1016\/j.ijrobp.2019.03.015"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026000824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026000824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T08:16:00Z","timestamp":1785917760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026000824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":30,"alternative-id":["S0167814026000824"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111443","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiotherapy with twice weekly Gemcitabine and Cisplatin compared to Cisplatin alone for organ preservation in muscle-invasive bladder cancer: results of the GETUG V04 randomized phase II trial","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111443","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111443"}}